{"id":"NCT01649856","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma","officialTitle":"A Comparative, Randomized, Parallel-group, Multi-center, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08-24","primaryCompletion":"2014-10-21","completion":"2016-09-16","firstPosted":"2012-07-25","resultsPosted":"2016-02-12","lastUpdate":"2017-10-11"},"enrollment":572,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma, Large B-Cell, Diffuse"],"interventions":[{"type":"DRUG","name":"CHOP","otherNames":[]},{"type":"DRUG","name":"rituximab [MabThera/Rituxan]","otherNames":[]},{"type":"DRUG","name":"rituximab [MabThera/Rituxan]","otherNames":[]}],"arms":[{"label":"A: Rituximab SC","type":"EXPERIMENTAL"},{"label":"B: Rituximab IV","type":"ACTIVE_COMPARATOR"}],"summary":"This multicenter, randomized, open label parallel-group study will evaluate the efficacy and safety of subcutaneous versus intravenous MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy in patients with previously untreated CD20-positive diffuse large B-Cell lymphoma. Patients will be randomized to receive either MabThera/Rituxan 1400 mg subcutaneously or MabThera/Rituxan 375 mg/m2 intravenously on Day 1 of each cycle for 8 cycles, in combination with 6-8 cycles of CHOP chemotherapy. Anticipated time on study treatment is 6 months.","primaryOutcome":{"measure":"Percentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu)","timeFrame":"Up to approximately 4.25 years","effectByArm":[{"arm":"Rituximab SC","deltaMin":50.6,"sd":null},{"arm":"Rituximab IV","deltaMin":42.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.076"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":186,"countries":["Algeria","Argentina","Belgium","Brazil","Bulgaria","Canada","Colombia","Finland","France","Greece","Ireland","Israel","Italy","Netherlands","Peru","Poland","Portugal","Russia","Saudi Arabia","Serbia","South Africa","Spain","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom","Venezuela"]},"refs":{"pmids":["28935843"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":155,"n":369},"commonTop":["Neutropenia","Alopecia","Anaemia","Nausea","Neutrophil count decreased"]}}